Clinical Trials Directory

Trials / Terminated

TerminatedNCT00560716

A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Cyclacel Pharmaceuticals, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.

Detailed description

Phase I study of an investigational cancer drug, CYC116, an Aurora kinase inhibitor, in patients with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGCYC116Dose escalation of CYC116

Timeline

Start date
2007-06-01
Primary completion
2009-01-01
Completion
2009-11-01
First posted
2007-11-20
Last updated
2021-12-22

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00560716. Inclusion in this directory is not an endorsement.

A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors (NCT00560716) · Clinical Trials Directory